Last, a comparison of the time to a recurrence between the treatment of the control cohort for MS and the treatment of the TecfideraTM cohort with TecfideraTM did not reach statistical significance ( Figure 6D ; Control cohort Interval B versus TecfideraTM cohort Interval C).
1
—
—